skip to Main Content

Learn more and share your knowledge with the liver community
Join the Live Tweeting @EASLedu for each EASL meeting

After an inspiring speech by Prof Yamada our four societies will redouble our efforts for hepatitis C elimination #easl #aasld #aleh #apasl

Dr Stephen Harrison presents phase 2 extension on Resmetiron THb agonist promoting lipid lowering, ALT& GGT decrease, improving proC3, PDFF-MRI T1c and adiponectin @AASLDtweets @EASLedu @LITMUS_IMI


Congratulation Jordi!! #AASLD #Award Very nice presentation by Prof Gores @BCLC_group @hospitalclinic @idibaps @CIBERehd @MayoClinic @AASLDtweets @EASLnews @liverunitclinic @AEEHLiver


Dr. Sangro: exciting early data for use of nivolumab (anti-PD1) + ipilimumab (anti-CTLA4) in advanced HCC, second line. Total response rate >30% with 8% complete response. Safety profile acceptable. Phase 3 trial (first line) is in progress 🙏 #LiverMtg19 #hcc #Immunotherapy

Back To Top